Ad-hoc-Meldung gemäß Art. 17 MAR in
Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
Schlagworte:
Study results/Weiteres Schlagwort
Eintritt der
Insiderinformationen:
19.11.2023
Ergänzende
Angaben:
Bayer Aktiengesellschaft: OCEANIC-AF study
stopped early due to lack of efficacy
Angaben zum Inhalt:
scrollen
Inhalt der
Ad-Hoc-Mitteilung:
EQS-Ad-hoc: Bayer Aktiengesellschaft / Key
word(s): Study results
Bayer Aktiengesellschaft: OCEANIC-AF study
stopped early due to lack of efficacy
19-Nov-2023 / 23:47 CET/CEST
Disclosure of an inside information acc. to
Article 17 MAR of the Regulation (EU) No 596/2014,
transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the
content of this announcement.
Leverkusen/Berlin, November 19, 2023
- OCEANIC-AF, a phase III study investigating
asundexian compared to apixaban (a direct oral
anticoagulant) in patients with atrial fibrillation
at risk for stroke is being stopped early. This
decision is based on the recommendation of the
study's Independent Data Monitoring Committee (IDMC)
as part of ongoing surveillance which showed an
inferior efficacy of asundexian versus the control
arm. Bayer will further analyze the data to
understand the outcome and publish the data.
Available safety data are consistent with
previously reported safety profiles of asundexian.
The IDMC recommends continuing the OCEANIC-STROKE
phase III study as planned. Appropriate measures will
be taken to close the OCEANIC-AF study and patients
will be contacted by their treating
physicians/investigators to discuss next steps.
Asundexian is an investigational agent and has
not been approved by any health authority for use in
any country, for any indication.
Forward-Looking Statements This release may contain forward-looking
statements based on current assumptions and forecasts
made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to
material differences between the actual future
results, financial situation, development or
performance of the company and the estimates given
here. These factors include those discussed in
Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes
no liability whatsoever to update these
forward-looking statements or to conform them to
future events or developments.
Contact:
Mr. Peter Dahlhoff, Bayer AG, Investor
Relations, Tel.: +49 214 60001494 , e-mail:
peter.dahlhoff@bayer.com
End of Inside Information
Information and Explanation of the Issuer to
this announcement:
About Bayer Bayer is a global enterprise with core
competencies in the life science fields of health
care and nutrition. Its products and services are
designed to help people and the planet thrive by
supporting efforts to master the major challenges
presented by a growing and aging global population.
Bayer is committed to driving sustainable development
and generating a positive impact with its businesses.
At the same time, the Group aims to increase its
earning power and create value through innovation and
growth. The Bayer brand stands for trust, reliability
and quality throughout the world. In fiscal 2022, the
Group employed around 101,000 people and had sales of
50.7 billion euros. R&D expenses before special
items amounted to 6.2 billion euros. For more
information, go to www.bayer.com.
19-Nov-2023 CET/CEST The EQS Distribution Services
include Regulatory Announcements, Financial/Corporate
News and Press Releases.
Archive at www.eqs-news.com
Language:
English
Company:
Bayer
Aktiengesellschaft
Kaiser-Wilhelm-Allee
1
51373 Leverkusen
Germany
Phone:
+49 (0)214
30-72704
E-mail:
ir@bayer.com
Internet:
www.bayer.com
ISIN:
DE000BAY0017
WKN:
BAY001
Indices:
DAX, EURO STOXX 50,
Stoxx 50
Listed:
Regulated Market in
Berlin, Dusseldorf, Frankfurt (Prime Standard),
Hamburg, Hanover, Munich, Stuttgart; Regulated
Unofficial Market in Tradegate Exchange
EQS News ID:
1776651
End of
Announcement
EQS News Service
1776651 19-Nov-2023 CET/CEST
Verweis auf andere
Meldung:
www.eqs-news.com
Angaben zum Emittenten:
scrollen
Name:
Bayer Aktiengesellschaft
Adresse:
Kaiser-Wilhelm-Allee 1, 51373 Leverkusen
E-Mail-Adresse:
ir@bayer.com
ISIN:
DE000BAY0017
WKN:
BAY001
Handelsplätze:
Regulated Market in Berlin, Dusseldorf,
Frankfurt (Prime Standard), Hamburg, Hanover,
Munich, Stuttgart; Regulated Unofficial Market in
Tradegate Exchange
Angaben zur
Pflichtmitteilung:
scrollen
Veröffentlichung
in elektronisch betriebenen
Informationsverbreitungssystem:
EQS Group AG, veröffentlicht über
Thomson Reuters, Bloomberg und vwd
Pflichtveröffentlichung am:
19.11.2023
Uhrzeit der
Veröffentlichung:
23:47:57
Pflichtveröffentlichung in/über:
EQS Group AG, veröffentlicht über
Thomson Reuters, Bloomberg und vwd